Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
TENOFOVIR DISOPROXIL 26,978 1,235 4.6% 3,617 216 48.2 yrs 31.8%
LAMIVUDINE 16,685 1,838 11.0% 3,442 423 43.0 yrs 35.2%
ENTECAVIR 4,487 726 16.2% 1,133 117 55.0 yrs 38.1%
TENOFOVIR ALAFENAMIDE 2,990 311 10.4% 713 38 58.6 yrs 39.3%
ADEFOVIR DIPIVOXIL 2,104 89 4.2% 709 8 55.1 yrs 27.0%

Head-to-Head Comparisons

TENOFOVIR DISOPROXIL vs LAMIVUDINE TENOFOVIR DISOPROXIL vs ENTECAVIR TENOFOVIR DISOPROXIL vs TENOFOVIR ALAFENAMIDE TENOFOVIR DISOPROXIL vs ADEFOVIR DIPIVOXIL LAMIVUDINE vs ENTECAVIR LAMIVUDINE vs TENOFOVIR ALAFENAMIDE LAMIVUDINE vs ADEFOVIR DIPIVOXIL ENTECAVIR vs TENOFOVIR ALAFENAMIDE ENTECAVIR vs ADEFOVIR DIPIVOXIL TENOFOVIR ALAFENAMIDE vs ADEFOVIR DIPIVOXIL
← Back to Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Class side effects →